Synthetic Toll-like receptor 4 agonist enhances vaccine efficacy in an experimental model of toxic shock syndrome
- PMID: 17715328
- PMCID: PMC2168172
- DOI: 10.1128/CVI.00153-07
Synthetic Toll-like receptor 4 agonist enhances vaccine efficacy in an experimental model of toxic shock syndrome
Abstract
The development of new protein subunit vaccines has stimulated the search for improved adjuvants to replace traditional aluminum-containing products. We investigated the adjuvant effects of a synthetic Toll-like receptor 4 (TLR4) agonist on vaccine efficacy in an experimental model of toxic shock syndrome. The TLR4 agonist E6020 has a simplified structure consisting of a hexa-acylated acyclic backbone. The vaccine examined is a recombinantly attenuated form of staphylococcal enterotoxin B (STEBVax). Using cells stably transfected with TLRs, E6020 transduced signals only through TLR4, suggesting monospecificity, while Escherichia coli 055:B5 lipopolysaccharide activated both the TLR2/6 heterodimer and TLR4. Coadministration of E6020 with STEBVax, by the intramuscular or intranasal route, induced significant levels of immunoglobulin G (IgG) in BALB/c mice. Further, increased IgG production resulted from the combination of E6020 with aluminum hydroxide adjuvant (AH). The antibody response to the vaccine coadministered with E6020 was a mixed Th1/Th2 response, as opposed to the Th2-biased response obtained with AH. Mice vaccinated with STEBVax coadministered with AH, TLR4 agonists, or a combination of both adjuvants were protected from toxic shock. Our data demonstrate the effectiveness of the synthetic TLR4 agonist E6020 as an alternative adjuvant for protein subunit vaccines that may also be used in combination with traditional aluminum-containing adjuvants.
Figures






Similar articles
-
Toll-like receptor 4 agonists adsorbed to aluminium hydroxide adjuvant attenuate ovalbumin-specific allergic airway disease: role of MyD88 adaptor molecule and interleukin-12/interferon-gamma axis.Clin Exp Allergy. 2008 Oct;38(10):1668-79. doi: 10.1111/j.1365-2222.2008.03036.x. Epub 2008 Jun 25. Clin Exp Allergy. 2008. PMID: 18631348
-
Synergism of toll-like receptor 2 (TLR2), TLR4, and TLR6 ligation on the production of tumor necrosis factor (TNF)-alpha in a spontaneous arthritis animal model of interleukin (IL)-1 receptor antagonist-deficient mice.Immunol Lett. 2009 Apr 27;123(2):138-43. doi: 10.1016/j.imlet.2009.03.004. Epub 2009 Mar 21. Immunol Lett. 2009. PMID: 19428561
-
TLR4 and MyD88 control protection and pulmonary granulocytic recruitment in a murine intranasal RSV immunization and challenge model.Vaccine. 2009 Jan 14;27(3):421-30. doi: 10.1016/j.vaccine.2008.10.073. Epub 2008 Nov 14. Vaccine. 2009. PMID: 19013492
-
E6020: a synthetic Toll-like receptor 4 agonist as a vaccine adjuvant.Expert Rev Vaccines. 2007 Oct;6(5):773-84. doi: 10.1586/14760584.6.5.773. Expert Rev Vaccines. 2007. PMID: 17931157 Review.
-
TLR2 signalling: At the crossroads of commensalism, invasive infections and toxic shock syndrome by Staphylococcus aureus.Int J Biochem Cell Biol. 2010 Jul;42(7):1066-71. doi: 10.1016/j.biocel.2010.03.021. Epub 2010 Apr 2. Int J Biochem Cell Biol. 2010. PMID: 20363358 Review.
Cited by
-
Increasing the Chemical Variety of Small-Molecule-Based TLR4 Modulators: An Overview.Front Immunol. 2020 Jul 10;11:1210. doi: 10.3389/fimmu.2020.01210. eCollection 2020. Front Immunol. 2020. PMID: 32765484 Free PMC article. Review.
-
A Novel Class of Small Molecule Agonists with Preference for Human over Mouse TLR4 Activation.PLoS One. 2016 Oct 13;11(10):e0164632. doi: 10.1371/journal.pone.0164632. eCollection 2016. PLoS One. 2016. PMID: 27736941 Free PMC article.
-
E6020, a TLR4 Agonist Adjuvant, Enhances Both Antibody Titers and Isotype Switching in Response to Immunization with Hapten-Protein Antigens and Is Diminished in Mice with TLR4 Signaling Insufficiency.J Immunol. 2022 Nov 15;209(10):1950-1959. doi: 10.4049/jimmunol.2200495. J Immunol. 2022. PMID: 36426935 Free PMC article.
-
A potential protein adjuvant derived from Mycobacterium tuberculosis Rv0652 enhances dendritic cells-based tumor immunotherapy.PLoS One. 2014 Aug 7;9(8):e104351. doi: 10.1371/journal.pone.0104351. eCollection 2014. PLoS One. 2014. PMID: 25102137 Free PMC article.
-
Examining the role of nasopharyngeal-associated lymphoreticular tissue (NALT) in mouse responses to vaccines.J Vis Exp. 2012 Aug 1;(66):3960. doi: 10.3791/3960. J Vis Exp. 2012. PMID: 22871688 Free PMC article.
References
-
- Boles, J. W., M. L. Pitt, R. D. LeClaire, P. H. Gibbs, E. Torres, B. Dyas, R. G. Ulrich, and S. Bavari. 2003. Generation of protective immunity by inactivated recombinant staphylococcal enterotoxin B vaccine in nonhuman primates and identification of correlates of immunity. Clin. Immunol. 108:51-59. - PubMed
-
- Chow, J. C., D. W. Young, D. T. Golenbock, W. J. Christ, and F. Gusovsky. 1999. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J. Biol. Chem. 274:10689-10692. - PubMed
-
- Corbel, M. J. 1996. Reasons for instability of bacterial vaccines. Dev. Biol. Stand. 87:113-124. - PubMed
-
- Fekety, F. R., Jr. 1969. Skin window studies of the effect of endotoxin upon the acute inflammatory response. Johns Hopkins Med. J. 124:291-295. - PubMed
-
- Fraser, J., V. Arcus, P. Kong, E. Baker, and T. Proft. 2000. Superantigens—powerful modifiers of the immune system. Mol. Med. Today 6:125-132. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources